Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  International Journal of Clinical and Experimental Pathology

• Publication date

  2014-01-15

• Fields of study

  Medicine

• Identifiers
  PMID 24551300PMCID PMC3925924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.

  2012cited by this paper
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• Emerging epigenetic targets and therapies in cancer medicine.

  2012cited by this paper
• High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma

  2011cited by this paper
• Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

  2009cited by this paper
• p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape

  2008cited by this paper
• The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome

  2008cited by this paper
• Expression of HDAC1 and CBP/p300 in human colorectal carcinomas

  2007cited by this paper
• Small cell lung cancer: have we made any progress over the last 25 years?

  2007cited by this paper
• Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias.

  2004cited by this paper
• CBP/p300 in cell growth, transformation, and development.

  2000cited by this paper
• c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300

  2000cited by this paper
• Conjunction dysfunction: CBP/p300 in human disease.

  1998cited by this paper
• The critical role of chromosome translocations in human leukemias.

  1998cited by this paper
• [Localization of a tumor suppressor gene distal to D22S270 in colorectal cancers].

  1997cited by this paper
• p300 gene alterations in colorectal and gastric carcinomas.

  1996cited by this paper
• The CBP co-activator is a histone acetyltransferase

  1996cited by this paper
• The transcriptional coactivators p300 and CBP are histone acetyltransferases.

  1996cited by this paper
• The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein

  1996cited by this paper
• Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP

  1995cited by this paper
• Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro.

  1995cited by this paper
• CBP‐induced stimulation of c‐Fos activity is abrogated by E1A.

  1995cited by this paper
• Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.

  1994cited by this paper
• E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators.

  1994cited by this paper
• Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma

  1993cited by this paper
• Heterogeneity for allelic loss in human breast cancer.

  1992cited by this paper
• Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma

  1992cited by this paper
• Small-cell lung cancer.

  1980cited by this paper

• Discovery of p300 histone acetyltransferase inhibitors bearing an imidazo[4,5-b]pyridine-2-one scaffold for the treatment of multiple myeloma.

  2026cites this paper
• A New Look at the Role of Radiation-Related Epigenetic Mechanisms in Diagnosis and Anticancer Therapies

  2025cites this paper
• Medicinal chemistry approaches to the discovery and development of p300/CBP inhibitors for cancer therapy.

  2025cites this paper
• Daidzein reprograms EP300/CREBBP-deficient immune evasion via targeting the PPARγ-ANGPT4/Tie2 axis in hypopharyngeal squamous cell carcinoma.

  2025cites this paper
• Comprehensive Characterization of HATs and HDACs in Human Cancers Reveals Their Role in Immune Checkpoint Blockade.

  2024cites this paper
• P300 reduces TUBB4B expression to facilitate the biological process of migration and invasion of non-small cell lung cancer cells.

  2024cites this paper
• Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.

  2023cites this paper
• Effects of the Acetyltransferase p300 on Tumour Regulation from the Novel Perspective of Posttranslational Protein Modification

  2023cites this paper
• C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification

  2022cites this paper
• Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.

  2022cites this paper
• NAA60 (HAT4): the newly discovered bi-functional Golgi member of the acetyltransferase family

  2022cites this paper
• Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells

  2022cites this paper
• Mass spectrometry‐based characterization of histones in clinical samples: applications, progress, and challenges

  2021cites this paper
• PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer

  2021cites this paper
• Role of histone acetyltransferase inhibitors in cancer therapy.

  2021cites this paper
• HISTome2: a database of histone proteins, modifiers for multiple organisms and epidrugs

  2020cites this paper
• Molecular and functional characterization of the role of the histone methyltransferase SETDB1 in malignant melanoma

  2020cites this paper
• Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta-analysis.

  2019cites this paper
• The role of HIF-1α, CBP and p300 in the regulation of Nav1.5 expression in breast cancer cells

  2019cites this paper
• H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy

  2019cites this paper
• Intratumoral heterogeneity of esophageal squamous cell carcinoma and its clinical significance.

  2019cites this paper
• The ZZ domain as a new epigenetic reader and a degradation signal sensor

  2019cites this paper
• Histone posttranslational modifications: Potential role in diagnosis, prognosis, and therapeutics of cancer

  2019cites this paper
• Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways

  2019cites this paper
• ROLE OF P300 ZZ DOMAIN IN CHROMATIN ASSOCIATION AND HISTONE ACETYLATION

  2018cites this paper
• The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma

  2018cites this paper
• The pregnane X receptor ( PXR ) and the nuclear receptor corepressor 2 ( NCoR 2 ) modulate cell growth in head and neck squamous cell carcinoma

  2018cites this paper
• Expression of the EP300, TP53 and BAX genes in colorectal cancer: Correlations with clinicopathological parameters and survival.

  2017cites this paper
• Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease.

  2017cites this paper
• β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells

  2017cites this paper
• Low CREBBP expression is associated with adverse long‐term outcomes in paediatric acute lymphoblastic leukaemia

  2017cites this paper
• Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma

  2017cites this paper
• CREB‐binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway

  2016cites this paper
• The role of CREBBP mutations in lymphoid malignancies

  2016influential citation
• P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line

  2016cites this paper
• CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response

  2016cites this paper
• Epigenetic mechanisms as key regulators in disease: Clinical implications

  2016cites this paper
• P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer

  2016cites this paper
• CREB-binding protein expression and the correlation with clinical aspects of oral squamous cell carcinoma

  2016cites this paper
• Epigenetic therapy in lung cancer and mesothelioma

  2015cites this paper
• Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.

  2015cites this paper
• Immunohistochemical evaluation of ROCK activation in invasive breast cancer

  2015cites this paper
• Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray

  2015cites this paper
• Targeting Head and Neck Cancer Stem Cells

  2015cites this paper
• Epigenetic drugs for cancer therapy

  2015cites this paper
• Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization.

  2014cites this paper
• Histone modifications: Targeting head and neck cancer stem cells.

  2014cites this paper
• KATs in Cancer: Functions and Therapies

  2014cites this paper